Staffan Welin

Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients

Papantoniou, Dimitrios; Fröss-Baron, Katarzyna; Garske Roman, Ulrike; Sundin, Anders et al.

Ingår i Journal of neuroendocrinology, 2024

• DOI för Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients
• Ladda ner fulltext (pdf) av Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients

Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers

Algeri, L.; Falkman, Lovisa; Spada, F.; Frassoni, S. et al.

Ingår i ESMO Open, 2024

• DOI för Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers
• Ladda ner fulltext (pdf) av Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers

The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation

Backman, Samuel; Botling, Johan; Nord, Helena; Ghosal, Suman et al.

Ingår i Journal of Pathology, s. 357-370, 2024

• DOI för The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation
• Ladda ner fulltext (pdf) av The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors

Falkman, Lovisa; Sundin, Anders; Skogseid, Britt; Botling, Johan et al.

Ingår i Upsala Journal of Medical Sciences, 2024

• DOI för Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
• Ladda ner fulltext (pdf) av Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors

Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort

Papantoniou, Dimitrios; Grönberg, Malin; Thiis-Evensen, Espen; Sorbye, Halfdan et al.

Ingår i Endocrine-Related Cancer, 2023

• DOI för Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
• Ladda ner fulltext (pdf) av Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort

Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients

Papantoniou, Dimitrios; Fröss-Baron, Katarzyna; Garske Roman, Ulrike; Sundin, Anders et al.

Ingår i Journal of neuroendocrinology, 2024

• DOI för Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients
• Ladda ner fulltext (pdf) av Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients

Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers

Algeri, L.; Falkman, Lovisa; Spada, F.; Frassoni, S. et al.

Ingår i ESMO Open, 2024

• DOI för Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers
• Ladda ner fulltext (pdf) av Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers

The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation

Backman, Samuel; Botling, Johan; Nord, Helena; Ghosal, Suman et al.

Ingår i Journal of Pathology, s. 357-370, 2024

• DOI för The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation
• Ladda ner fulltext (pdf) av The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors

Falkman, Lovisa; Sundin, Anders; Skogseid, Britt; Botling, Johan et al.

Ingår i Upsala Journal of Medical Sciences, 2024

• DOI för Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
• Ladda ner fulltext (pdf) av Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors

Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort

Papantoniou, Dimitrios; Grönberg, Malin; Thiis-Evensen, Espen; Sorbye, Halfdan et al.

Ingår i Endocrine-Related Cancer, 2023

• DOI för Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
• Ladda ner fulltext (pdf) av Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort

Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms.

Dam, Gitte; Grønbæk, Henning; Sundlöv, Anna; Botling, Johan et al.

Ingår i Acta Oncologica, s. 431-437, 2023

• DOI för Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms.

Overall Survival in Patients with Stage IV Pan-NET Eligible for Liver Transplantation

Kjaer, Josefine; Smith, Sara; Hellman, Per; Stålberg, Peter et al.

Ingår i World Journal of Surgery, s. 340-347, 2023

• DOI för Overall Survival in Patients with Stage IV Pan-NET Eligible for Liver Transplantation
• Ladda ner fulltext (pdf) av Overall Survival in Patients with Stage IV Pan-NET Eligible for Liver Transplantation

Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

Mollazadegan, Kazhan; Skogseid, Britt; Botling, Johan; Åkerström, Tobias et al.

Ingår i Endocrine Connections, 2022

• DOI för Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
• Ladda ner fulltext (pdf) av Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

Hörsch, Dieter; Anthony, Lowell; Gross, David J.; Valle, Juan et al.

Ingår i Neuroendocrinology, s. 298-309, 2022

• DOI för Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study
• Ladda ner fulltext (pdf) av Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

Central nervous system hemangioblastomas in von Hippel-Lindau disease: Total growth rate and risk of developing new lesions not associated with circulating VEGF levels

Sundblom, Jimmy; Persson Skare, Tor; Holm, Olivia; Welin, Staffan et al.

Ingår i PLOS ONE, 2022

• DOI för Central nervous system hemangioblastomas in von Hippel-Lindau disease: Total growth rate and risk of developing new lesions not associated with circulating VEGF levels
• Ladda ner fulltext (pdf) av Central nervous system hemangioblastomas in von Hippel-Lindau disease: Total growth rate and risk of developing new lesions not associated with circulating VEGF levels

Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors: A Propensity-Score Matched Cohort Study

Kjaer, Josefin; Clancy, Thomas E.; Thornell, Anders; Andersson, Niklas et al.

Ingår i Annals of Surgery Open, 2022

• DOI för Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors: A Propensity-Score Matched Cohort Study
• Ladda ner fulltext (pdf) av Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors: A Propensity-Score Matched Cohort Study

Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours

Almeamar, Hussein; Cullen, Lisa; Murphy, David J.; Crowley, Rachel K. et al.

Ingår i Journal of neuroendocrinology, 2022

• DOI för Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours

Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2

Papantoniou, Dimitrios; Grönberg, Malin; Landerholm, Kalle; Welin, Staffan et al.

Ingår i Endocrine, s. 893-904, 2021

• DOI för Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2
• Ladda ner fulltext (pdf) av Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2

177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Fröss-Baron, Katarzyna; Garske, Ulrike; Welin, Staffan; Granberg, Dan et al.

Ingår i Neuroendocrinology, s. 330-343, 2021

• DOI för 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants
• Ladda ner fulltext (pdf) av 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants

Adrenalectomy in ectopic Cushing's syndrome: A retrospective cohort study from a tertiary care centre

Lase, Ieva; Grönberg, Malin; Norlén, Olov; Stålberg, Peter et al.

Ingår i Journal of neuroendocrinology, 2021

• DOI för Adrenalectomy in ectopic Cushing's syndrome: A retrospective cohort study from a tertiary care centre

Ga-68-DOTATOC-PET/MRI and C-11-5-HTP-PET/MRI are superior to Ga-68-DOTATOC-PET/CT for neuroendocrine tumour imaging

Jawlakh, Hiba; Velikyan, Irina; Welin, Staffan; Sundin, Anders

Ingår i Journal of neuroendocrinology, 2021

• DOI för Ga-68-DOTATOC-PET/MRI and C-11-5-HTP-PET/MRI are superior to Ga-68-DOTATOC-PET/CT for neuroendocrine tumour imaging
• Ladda ner fulltext (pdf) av Ga-68-DOTATOC-PET/MRI and C-11-5-HTP-PET/MRI are superior to Ga-68-DOTATOC-PET/CT for neuroendocrine tumour imaging

Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Tiensuu Janson, Eva; Knigge, Ulrich; Dam, Gitte; Federspiel, Birgitte et al.

Ingår i Acta Oncologica, s. 931-941, 2021

• DOI för Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
• Ladda ner fulltext (pdf) av Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases

Kjaer, Josefin; Stålberg, Peter; Crona, Joakim; Welin, Staffan et al.

Ingår i BJS Open, 2021

• DOI för Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases
• Ladda ner fulltext (pdf) av Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases

A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors

Kjellman, Magnus; Knigge, Ulrich; Welin, Staffan; Thiis-Evensen, Espen et al.

Ingår i Neuroendocrinology, s. 840-849, 2021

• DOI för A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome

Dillon, Joseph S.; Kulke, Matthew H.; Hörsch, Dieter; Anthony, Lowell B. et al.

Ingår i Journal of Gastrointestinal Cancer, s. 212-221, 2021

• DOI för Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome
• Ladda ner fulltext (pdf) av Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome

Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission

Juhlin, Carl Christofer; Falhammar, Henrik; Kjellman, Magnus; Ahlen, Jan et al.

Ingår i BMC Gastroenterology, 2020

• DOI för Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission
• Ladda ner fulltext (pdf) av Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission

Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3

Ali, Abir Salwa; Perren, Aurel; Lindskog, Cecilia; Welin, Staffan et al.

Ingår i Scientific Reports, 2020

• DOI för Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3
• Ladda ner fulltext (pdf) av Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

Ali, Abir Salwa; Langer, Seppo W.; Federspiel, Birgitte; Hjortland, Geir Olav et al.

Ingår i PLOS ONE, 2020

• DOI för PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
• Ladda ner fulltext (pdf) av PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

High-grade progression confers poor survival in pancreatic neuroendocrine tumors

Botling, Johan; Lamarca, Angela; Bajic, Duska; Norlén, Olov et al.

Ingår i Neuroendocrinology, s. 891-898, 2020

• DOI för High-grade progression confers poor survival in pancreatic neuroendocrine tumors

Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing's syndrome

Lase, Ieva; Strele, Ieva; Grönberg, Malin; Kozlovacki, Gordana et al.

Ingår i Hormones, s. 351-360, 2020

• DOI för Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing's syndrome
• Ladda ner fulltext (pdf) av Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing's syndrome

Unmet Needs in Functional and Nonfunctional pancreatic neuroendocrine neoplasms

Jensen, Robert T.; Bodei, Lisa; Capdevila, J.; Couvelard, Anne et al.

Ingår i Neuroendocrinology, s. 26-36, 2019

• DOI för Unmet Needs in Functional and Nonfunctional pancreatic neuroendocrine neoplasms

Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Sorbye, Halfdan; Baudin, Eric; Borbath, Ivan; Caplin, Martyn et al.

Ingår i Neuroendocrinology, s. 54-62, 2019

• DOI för Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study

Lesén, Eva; Björstad, Ase; Björholt, Ingela; Marlow, Tom et al.

Ingår i Scandinavian Journal of Gastroenterology, s. 1509-1518, 2018

• DOI för Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study
• Ladda ner fulltext (pdf) av Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study

Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors

Krauss, Tobias; Ferrara, Alfonso Massimiliano; Links, Thera P.; Wellner, Ulrich et al.

Ingår i Endocrine-Related Cancer, s. 783-793, 2018

• DOI för Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Ali, Abir Salwa; Grönberg, Malin; Langer, Seppo W.; Ladekarl, Morten et al.

Ingår i Medical Oncology, 2018

• DOI för Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
• Ladda ner fulltext (pdf) av Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective

Crona, Joakim; Backman, Samuel; Welin, Staffan; Taieb, David et al.

Ingår i Cancers, 2018

• DOI för RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective
• Ladda ner fulltext (pdf) av RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske, Ulrike; Sandström, Mattias; Fröss-Baron, Katarzyna; Lundin, Lars et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 970-988, 2018

• DOI för Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
• Ladda ner fulltext (pdf) av Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Weickert, Martin O.; Kaltsas, Gregory; Hörsch, Dieter; Lapuerta, Pablo et al.

Ingår i Clinical Therapeutics, s. 952-962, 2018

• DOI för Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome
• Ladda ner fulltext (pdf) av Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study

Kjellman, M.; Knigge, U.; Welin, Staffan; Grønbæk, H. et al.

Ingår i Neuroendocrinology, s. 155-155, 2018

• DOI för Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study

Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Ali, Abir A.; Grönberg, Malin; Hjortland, G. O.; Grønbæk, H. et al.

Ingår i Neuroendocrinology, s. 184-184, 2018

• DOI för Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome

Dillon, J.; Kulke, M.; Warner, R.; Bergsland, E. et al.

Ingår i Neuroendocrinology, s. 224-224, 2018

• DOI för Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome

Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Weickert, Martin O.; Kaltsas, Gregory; Hörsch, Dieter; Lapuerta, Pablo et al.

Ingår i Pancreas, s. 357-358, 2018

• DOI för Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study

Dillon, Joseph S.; Kulke, Matthew H.; Pavel, Marianne; Horsch, Dieter et al.

Ingår i Pancreas, s. 337-338, 2018

• DOI för Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study

Association of a Prophylactic surgical approach to Stage IV Small Intestinal Neuroendocrine Tumors with Survival.

Daskalakis, Kosmas; Karakatsanis, Andreas; Hessman, Ola; Stuart, Heather C. et al.

Ingår i JAMA Oncology, s. 183-189, 2018

• DOI för Association of a Prophylactic surgical approach to Stage IV Small Intestinal Neuroendocrine Tumors with Survival.

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

Ali, Abir Salwa; Grönberg, Malin; Federspiel, Birgitte; Scoazec, Jean-Yves et al.

Ingår i PLOS ONE, 2017

• DOI för Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
• Ladda ner fulltext (pdf) av Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumors

Crona, Joakim; Norlén, Olov; Antonodimitrakis, Pantelis; Welin, Staffan et al.

Ingår i Pancreas, s. 441-441, 2017

• DOI för Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumors

A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors

Dumanski, Jan P.; Rasi, Chiara; Björklund, Peyman; Davies, Hanna et al.

Ingår i Endocrine-Related Cancer, s. 427-443, 2017

• DOI för A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors
• Ladda ner fulltext (pdf) av A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors

Plasma Protein Fingerprinting for the Diagnosis of Small Intestinal Neuroendocrine Tumors (siNETs)

Kjellman, M.; Knigge, U.; Welin, Staffan; Gronbaek, H. et al.

Ingår i Neuroendocrinology, s. 148-148, 2017

Impact of Concomitant Medication on Efficacy of Telotristat Ethyl - A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome

Anthony, L.; Kulke, M. H.; Hoersch, D.; Bergsland, E. et al.

Ingår i Neuroendocrinology, s. 212-212, 2017

Real-World Resource Use And Costs Of Treating Controlled And Uncontrolled Carcinoid Syndrome: A Retrospective Swedish Study

Lesen, E.; Bjorstad, A.; Bjorholt, I; Feuilly, M. et al.

Ingår i Value in Health, 2017

A Budget Impact Model Of The Addition Of Telotristat Ethyl Treatment In Patients With Uncontrolled Carcinoid Syndrome

Fust, K.; Maschio, M.; Pastor, M.; Kohli, M. et al.

Ingår i Value in Health, 2017

Real-World Resource Use And Costs Of Carcinoid Heart Disease In Patients With Neuroendocrine Tumors: A Retrospective Swedish Study

Bjorstad, A.; Marlow, T.; Lesen, E.; Bollano, E. et al.

Ingår i Value in Health, 2017

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification

Perren, Aurel; Couvelard, Anne; Scoazec, Jean-Yves; Costa, Frederico et al.

Ingår i Neuroendocrinology, s. 196-200, 2017

• DOI för ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

Öberg, Kjell; Couvelard, Anne; Delle Fave, Gianfranco; Gross, David et al.

Ingår i Neuroendocrinology, s. 201-211, 2017

• DOI för ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Kulke, Matthew H.; Hoersch, Dieter; Caplin, Martyn E.; Anthony, Lowell B. et al.

Ingår i Journal of Clinical Oncology, s. 14-23, 2017

• DOI för Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Telotristat Etiprate Shows Benefit in Treating Patients With Carcinoid Syndrome That is Inadequately Controlled by Somatostatin Analog Therapy in the Phase 3 TELESTAR Clinical Trial

Kulke, Matthew H.; Hoersch, Dieter; Caplin, Martyn; Anthony, Lowell et al.

Ingår i Pancreas, s. 478-478, 2016

Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog Therapy: Analysis of the Ongoing TELESTAR Extension Period

Hrsch, D.; Kulke, M.; Caplin, M.; Anthony, L. et al.

Ingår i Neuroendocrinology, s. 88-88, 2016

Expression of Mutated p53 Protein in Gastroenteropancreatic Neuroendocrine Carcinoma (WHO G3)

Ali, Abir; Grönberg, Malin; Federspiel, B.; Hjortland, G. O. et al.

Ingår i Neuroendocrinology, s. 43-43, 2016

Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours

Crona, Joakim; Norlén, Olov; Antonodimitrakis, Pantelis; Welin, Staffan et al.

Ingår i Journal of Clinical Endocrinology and Metabolism, s. 445-452, 2016

• DOI för Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours

Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome

Kulke, M.; Hoersch, D.; Caplin, M.; Anthony, L. et al.

Ingår i Annals of Oncology, 2016

• DOI för Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome

Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma

Crona, Joakim; Ljungström, Viktor; Welin, Staffan; Walz, Martin K. et al.

Ingår i PLOS ONE, 2015

• DOI för Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma
• Ladda ner fulltext (pdf) av Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma

COST-EFFECTIVENESS OF TREATING ADVANCED PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOR PATIENTS WITH EVEROLIMUS VERSUS SUNITINIB IN SWEDEN

Perrin, A.; Park, J.; Jacob, J.; Welin, Staffan

Ingår i Value in Health, 2015

Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)

Kulke, M. H.; Hoersch, D.; Caplin, M.; Anthony, L. et al.

Ingår i European Journal of Cancer, 2015

Targeted Next Generation Sequencing in the Screening for Familial Neuroendocrine Tumor Syndromes: A Tool for Personalized Medicine

Crona, Joakim; Stålberg, Peter; Granberg, Dan; Welin, Staffan et al.

Ingår i Neuroendocrinology, s. 253-253, 2014

Secondary Hormonal Syndromes in Patients with Sporadic Neuroendocrine Tumors

Crona, Joakim; Eriksson, Barbro; Welin, Staffan

Ingår i Neuroendocrinology, s. 240-240, 2014

Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma

Crona, Joakim; Verdugo, Alberto Delgado; Granberg, Dan; Welin, Staffan et al.

Ingår i Endocrine Connections, s. 104-111, 2013

• DOI för Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma

Treatment, prognostic markers and survival in thymic neuroendocrine tumours: A study from a single tertiary referral centre

Crona, Joakim; Björklund, Peyman; Welin, Staffan; Kozlovacki, Gordana et al.

Ingår i Lung Cancer, s. 289-293, 2013

• DOI för Treatment, prognostic markers and survival in thymic neuroendocrine tumours: A study from a single tertiary referral centre

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study

Sorbye, H; Welin, Staffan; Langer, S.W.; Vestermark, L.W. et al.

Ingår i Annals of Oncology, s. 152-160, 2013

• DOI för Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study

Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3)

Sorbye, Halfdan; Welin, Staffan; Langer, Seppo; Vestermark, Lena et al.

Ingår i Pancreas, s. 382-382, 2013

Combination chemotherapy in advanced adrenocortical carcinoma

Fassnacht, Martin; Terzolo, Massimo; Allolio, Bruno; Baudin, Eric et al.

Ingår i New England Journal of Medicine, s. 2189-2197, 2012

• DOI för Combination chemotherapy in advanced adrenocortical carcinoma

Gastric carcinoid in a patient infected with Helicobacter pylori: A new entity?

Antonodimitrakis, Pantelis; Tsolakis, Apostolos; Welin, Staffan; Kozlovacki, Gordana et al.

Ingår i World Journal of Gastroenterology, s. 3066-3068, 2011

• DOI för Gastric carcinoid in a patient infected with Helicobacter pylori: A new entity?

Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy

Welin, Staffan; Sorbye, Halfdan; Sebjornsen, Sigrunn; Knappskog, Stian et al.

Ingår i Cancer, s. 4617-4622, 2011

• DOI för Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy

Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®)

Kindmark, Henrik; Janson, Eva Tiensuu; Gustavsson, Bengt; Eriksson, Camilla et al.

Ingår i Acta Oncologica, s. 100-101, 2010

• DOI för Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®)

Chromogranin A is a Sensitive Marker for Detection of Recurrence in Neuroendocrine Tumors

Janson, Eva Tiensuu; Welin, Staffan; Eriksson, Barbro; Stridsberg, Mats

Ingår i Neuroendocrinology, s. 63-63, 2010

• DOI för Chromogranin A is a Sensitive Marker for Detection of Recurrence in Neuroendocrine Tumors

Elevated Plasma Chromogranin A is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumours

Welin, Staffan; Stridsberg, Mats; Cunningham, Janet; Granberg, Dan et al.

Ingår i Neuroendocrinology, s. 302-307, 2009

• DOI för Elevated Plasma Chromogranin A is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumours

Selective internal radiation therapy in patients with carcinoid liver metastases

Granberg, Dan; Garske, Ulrike; Welin, Staffan; Kindmark, Henrik et al.

Ingår i Acta Oncologica, s. 1169-1171, 2008

• DOI för Selective internal radiation therapy in patients with carcinoid liver metastases

Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years

Kindmark, Henrik; Sundin, Anders; Granberg, Dan; Dunder, Kristina et al.

Ingår i Medical Oncology, s. 330-337, 2007

• DOI för Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years

Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors

Granberg, Dan; Eriksson, Lars-Gunnar; Welin, Staffan; Kindmark, Henrik et al.

Ingår i Acta Radiologica, s. 180-185, 2007

• DOI för Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

Ekeblad, Sara; Sundin, Anders; Janson, Eva Tiensuu; Welin, Staffan et al.

Ingår i Clinical Cancer Research, s. 2986-2991, 2007

• DOI för Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

Welin, Staffan; Janson, Eva Tiensuu; Sundin, Anders; Stridsberg, Mats et al.

Ingår i European Journal of Endocrinology, s. 107-112, 2004

• DOI för High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

Treatment with Cisplatin and Etoposide in Patients with Neuroendocrine Tumors

Fjällskog, Marie-Louise; Granberg, Dan; Welin, Staffan; Eriksson, Christoffer et al.

Ingår i Cancer, s. 1101-1107, 2001

Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

Capdevila, Jaume; Ducreux, Michel; Garcia Carbonero, Rocio; Grande, Enrique et al.

Ingår i Neuroendocrinology, s. 1155-1167, 2022

• DOI för Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

Rodriguez-Freixinos, Victor; Capdevila, Jaume; Pavel, Marianne; Thawer, Alia et al.

Ingår i European Journal of Cancer, s. 200-214, 2021

• DOI för Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma

Mollazadegan, Kazhan; Welin, Staffan; Crona, Joakim

Ingår i Current Treatment Options in Oncology, 2021

• DOI för Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma
• Ladda ner fulltext (pdf) av Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma

Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis

Crona, Joakim; Lamarca, Angela; Ghosal, Suman; Welin, Staffan et al.

Ingår i Endocrine-Related Cancer, s. 539-550, 2019

• DOI för Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Janson, Eva Tiensuu; Sorbye, Halfdan; Welin, Staffan; Federspiel, Birgitte et al.

Ingår i Acta Oncologica, s. 1284-1297, 2014

• DOI för Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Midgut Carcinoid Tumours: New Diagnostic Procedures and Treatment

Welin, Staffan

2007

• Ladda ner fulltext (pdf) av Midgut Carcinoid Tumours: New Diagnostic Procedures and Treatment